| Literature DB >> 28979376 |
Kate Colette Tatham1, Kieran Patrick O'Dea1, Kenji Wakabayashi1,2, Nandor Marczin1,3, Masao Takata1.
Abstract
Whilst lung transplantation is a viable solution for end-stage lung disease, donor shortages, donor lung inflammation and perioperative lung injury remain major limitations. Ex vivo lung perfusion has emerged as the next frontier in lung transplantation to address and overcome these limitations, with multicentre clinical trials ongoing in the UK, rest of Europe and North America. Our research seeks to identify the poorly understood cellular and molecular mechanisms of primary graft dysfunction through the development of an isolated perfused lung model of transplantation and investigation of the role of pulmonary inflammation in this paradigm.Entities:
Keywords: EVLP; Lung transplantation; ischaemia-reperfusion
Year: 2014 PMID: 28979376 PMCID: PMC5593288 DOI: 10.1177/1751143714554062
Source DB: PubMed Journal: J Intensive Care Soc ISSN: 1751-1437